

12:50 – 2:00PM	1 hr 10 min	Farid Vij, Ciitizen Lukas Lange, Probably Genetic Rick Barkley, Everlum Paul Kruszka, Gene Dx Madeleine Braun, Jackson Labs Nina Gonzaludo, PacBio Rachel Thomas, Elpida	Resources for Rare Disease Organizations	<i>Opportunity to learn about a variety of services (for profit) offered to the rare disease community for the advancement of rare disease research.</i>
2:00 – 2:45 PM	45 min	Mike Graglia, SynGAP Research Fund, Inc.	Early Research Funding: Parent Experience	<i>Mike Graglia, Founder of the SynGAP Research Fund will share his personal experiences in building a disease foundation from scratch and funding strategies.</i>
2:45 – 3:45 PM	1 hr	Tom Kassberg, Ultragenyx Neil Kumar, BridgeBio Shalini Sharp, Neurocrine Biosciences	Panel Discussion: Late-stage Funding – Partnerships and VCs	<i>Tom Kassberg, CBO of Ultragenyx, Neil Kumar, CEO of BridgeBio, and Shalini Sharp, Board Member of Neurocrine Biosciences, will lead a panel discussion on partnering and funding.</i>
3:45 – 4:00PM	15 min	BREAK		
4:00 – 4:45 PM	45 min	Sunitha Malepati, CACNA1A Foundation	Rare Parents as Drug Development Catalysts	<i>Sunitha Malepati, Vice President & Treasurer of CACNA1A Foundation will share her parent journey through rare disease and involvement with the CACNA1A Foundation.</i>



syngap.fund/ultra




SYNGAP RESEARCH FUND

Collaboration. Transparency. Urgency.



Tony, 1



Tony, 2





Tony, 3



Tony's Dx Journey - How many fall through the cracks?

- Delays evident at 2, one clear seizure at 3, EEG confirming Epilepsy
- First, a negative CMA, then Invitae Panel leading to VUS confirmed by RNA Seq. Pathogenic diagnosis just after 4th birthday.
- **Two places where most people stop: CMA negative & VUS.**





We launched SRF with a commitment to give \$1m in SYNGAP1

SYNGAP RESEARCH FUND
Collaboration. Transparency. Urgency.

About SYNGAP1 ▾

About SRF ▾

Professionals ▾


Families ▾

News & Events ▾



Donate

Intro w/ Tony



Read more about Tony on [his Warrior Story](#).

Mike - Tony's Dad & SRF's Founder

Left my career a few years ago to lead SRF. In addition to working with the team of SynGAP families and partners, I serve on Executive Board of COMBINEDBrain, AES Epilepsy Research Benchmarks Stewards Committee and work closely with Innovation and Value Initiative Methods Summit & Personalized Medicine Coalition and FasterCures LeadersLink.










Professional background in global development, healthcare strategy, finance and planning at top-tier institutions.



Educational background in Mathematics (BS), International Economics (MA) and Finance (MBA).




SYNGAP1 Timeline




304 PubMed.gov results for SYNGAP1 from 1998 to 12 November 2024

SYNGAP1 highly associated with Autism



Satterstrom et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. *Cell*. **2020** Feb 6;180(3):568-584.e23.



Fu JM, Satterstrom FK, Peng M, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. *Nat Genet*. **2022**;54(9):1320-1331.

#SyngapCensus - Patients known to SRF 4x in 4 years



How many people have SYNGAP1?
3Q24 #SYNGAPcensus = 1,497
Details: [Syngap.Fund/Census](https://syngap.fund/census)





SYNGAP1 THERAPEUTIC PIPELINE | 2024

DISCOVERY

PRECLINICAL

IN HUMAN

FDA REVIEW
& APPROVAL

Small Molecule

Ruber Internacional | HOSPITAL

Fenfluramine



4-PB for increased protein function



AXNIS

KCC2 potentiation for E/I balance

nospharma

NOS-01, novel combination therapy



Rarebase

FDA-appr mRNA upregulation hits



CHOW

FDA-appr phenotypic rescue hits



UNRAVEL

rareSHIFT™ & BioNAV™



4M THERAPEUTICS

4M Tx GSK3β Inhibitor

ASO

STROKE

ACADIA

TANGO Restore ASO platform

PRAxis

SOLIDUS ASO platform

ENDD

ASO

CAMP4

ASO

QuiverBioscience

ASO

AAV based

Regel

ENDD

CRISPR-based epigenome targeting

Multiple strategies

TEVARD

Confidential

Suppressor/Enhancer tRNA platform

Novel gene therapy product


Cell




UC DAVIS

Hematopoietic stem cell therapy

Overview: SRF in numbers



Growing volume and cost of grants



It gets complicated fast - I have ~20 grants in flight today.

Year	Institution	Prof/Focus	Commitment	= Remaining +	Year	Institution	Prof/Focus	Commitment	= Remaining +
2018	Hopkins	Huganir	\$500,000	Fully Funded	2022	Rarebase	FM 38, 40, 41, 45	\$570,000	\$213,750
2018	Scripps	Rumbaugh	\$205,500	Fully Funded	2022	Hopkins	Coller	\$130,000	\$65,000
2018	Baylor	Holder	\$130,000	Fully Funded	2022	Edinburgh	Cobb/Kind	\$183,545	\$183,545
2019	UCSF	Lowenstein	\$10,000	Fully Funded	2022	USC	Quadrato	\$130,000	\$41,043
2019	Penn	Heller	\$130,000	Fully Funded	2022	Harvard/BCH/Axor	Xin/Kadam	\$140,000	Fully Funded
2020	Ciitizen	Brimble	\$40,000	Fully Funded	2023	Cornell	Cunnane (Med Stu)	\$5,000	Fully Funded
2020	USC	Coba / Quadrato	\$46,500	Fully Funded	2023	Utah	Chow	\$65,377	Fully Funded
2020	JCU	Frazier	\$14,200	Fully Funded	2024	AES/CHOP	McKee	\$10,000	Fully Funded
2020	USC	Coba	\$130,000	Fully Funded	2023	Stanford	Knowles	\$130,000	\$65,000
2021	Harvard	DSC	\$70,191	Fully Funded	2023	JCU	Frazier	\$105,000	\$13,609
2021	Harvard	Poduri	\$238,133	\$65,133	2023	Turku	Postilla	\$100,000	\$50,000
2021	Rarebase	IPSC	\$63,750	Fully Funded	2023	Toronto	Andrade	\$156,380	\$78,190
2021	Combined Brain	IPSC	\$1,286	Fully Funded	2023	Ottawa	Lacoste	\$25,000	\$15,000
2021	Rarebase	Function, round 1	\$150,000	Fully Funded	2023	Cornell	Grinspan	\$100,000	\$100,000
2022	Canada Models	UBC & Montreal	\$19,672	Fully Funded	2023	NYU	Devinsky	\$50,000	\$50,000
2022	Nebraska	Zempleni	\$99,909	Fully Funded	2023	Florey	Waters	\$7,000	\$7,000
2022	Probably Genetic	Lukas Lange	\$15,600	Fully Funded	2023	Jax	Simon	\$186,700	\$186,700
2022	UC Davis	Joe Anderson	\$148,000	\$20,000	2023	Nebraska	Zempleni	\$196,672	\$196,672
2022	Fundacion NICE	Aledo	\$1,250	Fully Funded	2024	UCSF	Willsey	\$130,000	\$130,000
2022	Penn	MDBR	\$65,000	Fully Funded	2024	U. Ottawa	Lacoste	\$128,888	\$128,888
2022	Jackson Labs	TBD	\$42,700	\$15,647	2024	Edinburgh (UK)	Donlin-Asp	\$130,000	\$130,000
2022	Turku	Courtney	\$187,299	\$0	2024	Jax	Simon	\$186,700	\$186,700
2022	McGill	Bowie	\$115,000	\$58,388				\$5,290,252	\$2,000,265


2023 Event Recap

- Million Dollar Bike Ride | *\$31k raised + \$30k match*
- Sprint4Syngap | *\$252k raised*
 - Tavillas carry this event (*\$166k raised*)
- 3rd Annual Cannonball for a Cure | *\$130k raised*
- 3rd Annual SRF Gala (Caren Leib) | *\$80k raised*
- 2nd Annual Scramble for Syngap | *\$25k raised*
- 2nd Syngap Soiree | *\$300k+ raised*
- 1st Annual Syngap Paddleslap | *\$20k raised*



		2018	2019	2020	2021	2022	2023	2024 YTD 11/13	Total
990 Revenue (line 12)	A	\$20,000	\$382,888	\$590,087	\$1,357,074	\$2,189,895	\$1,859,673	\$1,494,668	\$7,894,285
990 Expense (line 18)	B	0	\$52,910	\$225,407	\$874,679	\$1,192,705	\$2,151,196	\$1,501,675	\$5,998,572
Net	A - B	\$20,000	\$329,978	\$364,680	\$482,395	\$997,190	-\$291,523	-\$7,007	\$1,895,713
Direct Payments	F = C+D+E	\$361,833	\$0	\$0	\$250,000	\$0	\$0	\$0	\$611,833
Total SRF Raised	G = A+F	\$381,833	\$382,888	\$590,087	\$1,607,074	\$2,189,895	\$1,859,673	\$1,494,668	\$8,506,118
Total SRF Spent	H = B+F	\$361,833	\$52,910	\$225,407	\$1,124,679	\$1,192,705	\$2,151,196	\$1,501,675	\$6,610,405
Spend	H/G	94.8%	13.8%	38.2%	70.0%	54.5%	115.7%	100.5%	77.7%
Founders Gifts to SRF	I	\$20,000	\$51,701	\$51,758	\$209,317	\$175,000	\$256,080	\$300,000	\$1,063,856
Founders Direct giving	C	\$111,833	\$0	\$0	\$0	\$0	\$0	\$0	\$111,833
Total Founder Spend	K = I + C	\$131,833	\$51,701	\$51,758	\$209,317	\$175,000	\$256,080	\$300,000	\$1,175,690
% SRF Revenue	K/G	34.53%	13.50%	8.77%	13.02%	7.99%	13.77%	20.07%	13.82%
Founders Soft Credits	L	0	\$255,000	\$84,500	\$51,079	\$233,006	\$245,920	\$455,000	\$1,324,505
Founder Direct Donors	M = D+E	\$250,000			\$250,000		0	0	\$500,000
Total Founder Impact	N = K + L + M	\$381,833	\$306,701	\$136,258	\$510,396	\$408,006	\$502,000	\$755,000	\$3,000,195
% SRF Revenue	N/G	100.00%	80.10%	23.09%	31.76%	18.63%	26.99%	50.51%	35.27%
Jones	O				\$93,307	\$326,000	\$345,166	\$90,841	\$855,314
Tavilla	P				\$11,894	\$189,784	\$229,369	\$89,930	\$520,978
Stelmaszek	Q				\$2,114	\$133,921	\$120,203	\$51,629	\$307,866
Kessler	R				\$31,197	\$81,073	\$71,405	\$77,542	\$261,217
Foster/Freirich	S				\$20,000	\$45,000	\$108,503	\$61,954	\$235,457
Miles	T				\$400	\$27,412	\$18,674	\$24,980	\$71,466
U = O+P+Q+R+S+T					\$158,912	\$803,190	\$893,320	\$396,876	\$2,252,298
	U/G				9.89%	36.68%	48.04%	26.55%	26.48%




		2018	
990 Revenue (line 12)	A	\$20,000	
990 Expense (line 18)	B	0	
Net	A - B	\$20,000	
Direct Payments	F = C+D+E	\$361,833	
Total SRF Raised	G = A+F	\$381,833	
Total SRF Spent	H = B+F	\$361,833	
Spend	H/G	94.8%	
Founders Gifts to SRF	I	\$20,000	
Founders Direct giving	C	\$111,833	
Total Founder Spend	K = I + C	\$131,833	
% SRF Revenue	K/G	34.53%	
Founders Soft Credits	L	0	
Founder Direct Donors	M = D+E	\$250,000	
Total Founder Impact	N = K + L + M	\$381,833	
% SRF Revenue	N/G	100.00%	
Jones	O		
Tavilla	P		
Stelmaszek	Q		
Kessler	R		
Foster/Freirich	S		
Miles	T		
U = O+P+Q+R+S+T			
	U/G		



22	2023	2024 YTD 11/13	Total
\$189,895	\$1,859,673	\$1,494,668	\$7,894,285
\$192,705	\$2,151,196	\$1,501,675	\$5,998,572
\$997,190	-\$291,523	-\$7,007	\$1,895,713
\$0	\$0	\$0	\$611,833
\$189,895	\$1,859,673	\$1,494,668	\$8,506,118
\$192,705	\$2,151,196	\$1,501,675	\$6,610,405
\$175,000	\$256,080	\$300,000	\$1,063,856
\$0	\$0	\$0	\$111,833
\$175,000	\$256,080	\$300,000	\$1,175,690
\$233,006	\$245,920	\$455,000	\$1,324,505
\$0	0	0	\$500,000
\$408,006	\$502,000	\$755,000	\$3,000,195
\$326,000	\$345,166	\$90,841	\$855,314
\$189,704	\$229,369	\$89,930	\$520,978
\$33,921	\$120,222	\$51,629	\$307,866
\$81,073	\$71,405	\$77,542	\$261,217
\$45,000	\$108,503	\$61,954	\$235,457
\$27,412	\$18,674	\$24,300	\$71,466
\$803,190	\$893,320	\$396,876	\$2,252,298
36.68%	48.04%	26.55%	26.48%

A guarantee fund can allow you to move faster

We can't raise funds till we have a project and we can't start a project till we have funds...



What I think is important after working on this for 5+ years

Three Essential Concepts - These are ideas that you have to embrace if you are seriously going to do some fundraising

Four Major Learnings - Realizations I've had along the way and want you to know.

Ten helpful tips - These are things I've learned, generally by doing the opposite first. I have iterated relentlessly and made so many mistakes.

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)


Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	20,000.	382,888.	590,087.	1,364,391.	2,144,228.	4,501,594.
2 Tax revenue levied for the						

You are exactly where you need to be.

Don't waste time doubting yourself, your loved ones can't afford it.

Jump in and own what you are doing, it's incredibly hard and important. You can't afford self-sabotage.




The universe is naturally abundant

You have to have this mindset if you are fundraising.

Do not talk yourself out of believing you will find the money.

If you don't believe it, who will?




Our capital is rare - Seed, Risk tolerant & Catalytic

What do you say when they ask “Why should I give you money?”

Our deep commitment to disease X means we will take risks nobody else will, this isn't an opportunity, it's an obligation.

It can be catalytic to other capital — otherwise we are kidding ourselves — we are also scaffolding or de-risking the target.

1. Getting researchers data for larger grants and seeing out assets in their labs.
2. Scaffolding the target - Developing assets like iPSCs or models.
3. De-risking the target - Developing clinical trial endpoints, natural history, etc.




e.g. Your work increases your scores on tables like this.

Disease Name	US / EU Prevalence	Target Gene	Gene Size	Inher.		Onset	Tx Mech.	Nat. Hist.	PC Mod.	Clin. Dev.	Pat. Org.	SZ	ID	MD	Clin. Need	Mkt. Opp.	Disease Summary
Internal Development Candidates - Genetic Neurodevelopmental Disorders & Epileptic Syndromes																	
SCN2A-Related Disorders	62,133	SCN2A	6,018	AD		<12 m	4	5	4	4	5	4	5	3	5	5	Moderate-severe ID, autism; refractory epilepsy
SCN8A-Related Disorders	57,275	SCN8A	5,943	AD		<6 m	3	5	4	3	4	3	5	4	4	5	Severe ID, refractory epilepsy with regression
Dravet Syndrome	56,031	SCN1A	5,997	AD		<12 m	5	5	5	5	5	5	5	4	5	3	Severe-profound ID, DD & intractable epilepsy
CHD2 Encephalopathy	53,183	CHD2	5,487	AD		<2 y	5	5	4	4	1	5	4	2	4	5	Moderate-severe ID with refractory epilepsy
Phelan-McDermid Syndrome	51,321	SHANK3	5,193	AD		<2 y	5	5	4	4	5	4	5	4	5	5	Moderate-severe ID, DD autism; seizures in 40%
SYNGAP1 Encephalopathy	47,491	SYNGAP1	4,032	AD		<2 y	5	5	5	5	5	5	5	4	5	5	Severe ID with up to ~200 seizures per day
GRIN2B-Related Disorder	45,960	GRIN2B	4,455	AD		<4 y	4	4	1	3	5	4	5	4	4	4	Moderate-severe ID; 50% epilepsy, >25% autism
KIF1A Neurological Disorder	40,559	KIF1A	5,073	AD		<2 y	4	4	3	4	5	3	4	4	5	5	Severe ID, epilepsy; regression
Reit Syndrome	38,879	MECP2	1,461	XL		<18 m	4	5	5	4	5	4	5	5	5	4	Neurodegeneration with ID, autism & early death
Smith-Magenis Syndrome	31,103	RAI1	5,721	AD		<6 m	5	4	5	4	5	2	5	3	4	5	Moderate ID, DD with autism; no epilepsy
DNM1 Encephalopathy	29,408	DNM1	2,595	AD		~6 m	4	5	5	5	5	5	5	5	5	5	Profound ID, DD with intractable epilepsy
STXP1 Encephalopathy	28,108	STXP1	1,785	AD		<6 m	5	5	4	5	5	5	5	4	5	5	Profound ID, DD with resistant epilepsy & autism
KCNQ2 Encephalopathy	25,467	KCNQ2	2,619	AD		<1 m	4	4	4	4	5	5	5	5	5	5	Severe ID, DD and neonatal onset epilepsy
SLOC1A1-Related Disorder	20,603	SLOC1A1	1,800	AD		<4 y	5	4	2	4	5	4	4	3	4	5	Moderate ID, epilepsy with regression
CDKL5 Deficiency Disorder	16,868	CDKL5	2,883	XL		<3 m	4	5	4	5	5	5	5	5	5	3	Devastating DD, ID & epilepsy
GABRB3 Associated Epilepsy	16,633	GABRB3	5,783	AD		<12 m	4	5	4	4	3	4	4	3	4	5	Moderate ID, resistant epilepsy; ~25% autism
SETD5 Syndrome	12,366	SETD5	4,329	AD		<2 y	5	4	5	3	2	1	4	2	4	5	Moderate ID & DD; ~25% autism
PRRT2 Dyskinesia & Epilepsy	11,664	PRRT2	1,023	AD		<1 y	4	4	4	3	1	4	3	4	3	4	Infantile epilepsy, dyskinesia; some ID
CACNA1A-Related Disorders	7,776	CACNA1A	7,527	AD		<10 y	4	3	3	4	5	4	2	4	3	4	Highly variable spectrum
GLUT1 Deficiency Syndrome	7,422	SLC2A1	1,479	AD		<1 y	5	5	5	4	5	5	4	5	4	4	Moderate ID, DD, epilepsy & motor disorder


Language & culture matters: “*We can fill an unmet need together*” vs “*I need to raise \$100k*”.

The sooner you go to the community with a project and urge them to support it, the sooner this gets real.

In addition to fundraising you are activating a community.



How you fundraise will change as you grow,



It's darkest before the dawn

A stalled fundraiser feels like a public failure, it's not.

These gaps are when people who can fill gaps step forward.




The screenshot shows a press release on the Cision website. The header includes the Cision logo and a 'Send a Release' button. The main headline reads 'SynGAP Research Fund Announces Grant to Heller Lab of Neuroepigenetics'. To the right of the headline is the SynGAP Research Fund logo, which is a circular emblem with the text 'SYNGAP RESEARCH FUND' and 'Collaboration. Transparency. Urgency.' around a central graphic. Below the headline, it states 'NEWS PROVIDED BY SynGAP Research Fund' with a right-pointing arrow and the date '19 Nov, 2020, 09:21 ET'. A 'SHARE THIS ARTICLE' section follows with icons for Facebook, Twitter, LinkedIn, Pinterest, Email, and Print. The body text begins with 'PALO ALTO, Calif., Nov. 19, 2020 /PRNewswire/ -- The SynGAP Research Fund (SRF) announces a new research grant award to the Heller Laboratory of Neuroepigenetics in the Perelman School of Medicine at the University of Pennsylvania. The lab will receive \$130,000 over two years towards funding a postdoctoral fellow who will focus on epigenetic regulation of SynGAP1.'

SynGAP Research Fund
Announces Grant to Heller Lab
of Neuroepigenetics

NEWS PROVIDED BY
SynGAP Research Fund →
19 Nov, 2020, 09:21 ET

SHARE THIS ARTICLE

PALO ALTO, Calif., Nov. 19, 2020 /PRNewswire/ -- The SynGAP Research Fund (SRF) announces a new research grant award to the Heller Laboratory of Neuroepigenetics in the Perelman School of Medicine at the University of Pennsylvania. The lab will receive \$130,000 over two years towards funding a postdoctoral fellow who will focus on epigenetic regulation of SynGAP1.




Donors don't love overhead, be ready to discuss.

Option 1: Good news we don't spend much on overhead!

You are just starting and working on a shoestring, so go ahead and own that.

Put a time limit on it.



Option 2: Refocus the conversation on capacity building.

We need a dedicated organization for this disease and organizations need funding to grow.


Help with your Ws: Wealth, Wisdom or Work.



10 Tips

1. Hire someone, this is a ton of work - Virtual assistant or parent.
2. Plumbing matters, don't ignore it - Scalable tech to move & track money.
3. Communicate relentlessly - Podcast/Videos, Social, Newsletter.
4. Call people to thank and to ask - You learn what matters in calls.
5. Throw an annual event ASAP - Events trigger donations, get it going.
6. Don't pay overheads to large institutions - They get it, put policy on your site.
7. Press Releases matter, use them. - Eureka Alerts is reasonable.
8. Newly diagnosed families panic, give them something to do. - Page for kiddo.
9. Don't skip the audit - These are useful, credibility building and not that bad.
10. Liquidate stocks upon receipt - You are not in the stock business.

SRF has three SYNGAP1 podcasts for patient finding & support



SynGAP10 weekly 10 minute updates on SYN Syngap Research Fund, 501(c)(3)

★ 5 (70) · NON-PROFIT · UPDATED WEEKLY



SYNGAP1 Stories

Syngap Research Fund, 501(c)(3)

PARENTING · UPDATED BIWEEKLY



Café SYNGAP1

Syngap Research Fund, 501(c)(3)

PARENTING · UPDATED BIWEEKLY

Bienvenidos al nuevo podcast de SRF en Español: Café Syngap1 pretender ser un espacio para encontrar apoyo, consejos y esperanza en una comunidad de Padres, Hermanos, Investigadores, Científicos, Terapeutas. [MORE](#)

▶ Latest Episode



Episodes ▼

SATURDAY · VIDEO

113. Fondo sets the bar for LatAm Engage 2nd Soiree was a hit, grants are rolling in!

Super Heroine: Vicky Arteaga Fondo Syngap is tireless
<https://www.syngapresearchfund.org/professionals/2C>

Episodes ▼

AUGUST 29

Mike Graglia, SRF Managing Dir. & SYNGAP1 difficult. Tony's experience shows that it's

Show Notes Going back to school is difficult for most and other rare diseases, it is especially hard! Mike Gra

Episodes ▼

AUGUST 20

▶ **Episodio 01: Valeria Torcetta y su hija Charo- La Primera Paciente Diagnosticada con SynGAP1 en America Latina**

Episodio #01 Bienvenidos a nuestro nuevo podcast, Café Syngap1! En nuestro primer episodio, nos acompaña Valeria Torcetta, una invitada especial quien nos habla sobre Charo, su hija con Syngap1, y primera pa...

53 min



Tony, 7



Tony, 10



Thank you.
mike@cureSYNGAP1.org

@cureSYNGAP1



Build community and leverage giving: 1:2:6

		2018	2019	2020	2021	2022	Total	Notes
990 Revenue (line 12)	A	\$20,000	\$382,888	\$590,087	\$1,357,074	\$2,144,228	\$4,494,277	
990 Expense (line 18)	B	0	\$52,910	\$225,407	\$874,679	\$1,192,705	\$2,345,701	
Net	A - B	\$20,000	\$329,978	\$364,680	\$482,395	\$951,523	\$2,148,576	
Direct Payments	F = C+D+E	\$361,833	\$0	\$0	\$250,000	\$0	\$611,833	Donors direct
Total SRF Raised	G = A+F	\$381,833	\$382,888	\$590,087	\$1,607,074	\$2,144,228	\$5,106,110	
Total SRF Spent	H = B+F	\$361,833	\$52,910	\$225,407	\$1,124,679	\$1,192,705	\$2,957,534	
Spend	H/G	94.8%	13.8%	38.2%	70.0%	55.6%	57.9%	
Founders Gifts to SRF	I	\$20,000	\$51,701	\$51,758	\$209,317	\$175,000	\$507,776	
Founders Gifts via other	J	0	\$0	\$0	\$0	\$0	0	Need to find t
Founders Direct giving	C	\$111,833	\$0	\$0	\$0	\$0	\$111,833	
Total Founder Spend	K = I + J + C	\$131,833	\$51,701	\$51,758	\$209,317	\$175,000	\$619,610	62.
% SRF Revenue	K/G	34.53%	13.50%	8.77%	13.02%	8.16%	12.13%	
Founders Soft Credits	L	0	\$255,000	\$84,500	\$51,079	\$233,006	\$623,585	Conservative
Founder Direct Donors	M = D+E	\$250,000	0	0	\$250,000	195000	\$695,000	
Total Founder Impact	N = K + L + M	\$381,833	\$306,701	\$136,258	\$510,396	\$603,006	\$1,938,195	
% SRF Revenue	N/G	100.00%	80.10%	23.09%	31.76%	28.12%	37.96%	